Log out
My profile and settings
My bookmarks
Comment history
Please complete your account verification. Resend verification email.
This verification token has expired.
Your email address has been verified. Update my profile.
Your account has been deactivated. Sign in to re-activate your account.
View all newsletters in the newsletter archive
You are now unsubscribed from receiving emails.
Sorry, we were unable to unsubscribe you at this time.
Back to profile
Comment Items
You have not left any comments yet.
you replied to a comment:
Saved Posts
You haven’t bookmarked any posts yet.

When I think of the holidays, two things always come to mind: matching pajama sets—a tradition in my family—and, of course, holiday music.

Read more
Become a Gates Notes Insider
Sign up
Log out
Personal Information
This email is already registered
Please verify email address. Click verification link sent to this email address or resend verification email.
Email and Notification Settings
Send me updates from Bill Gates
You must provide an email
Send me Gates Notes survey emails
Send me the weekly Top of Mind newsletter
Email me comment notifications
On-screen comment notifications
Select interests to personalize your profile and experience on Gates Notes.
Saving Lives
Energy Innovation
Improving Education
Book Reviews
About Bill Gates
Account Deactivation
Click the link below to begin the account deactivation process.
If you would like to permanently delete your Gates Notes account and remove it’s content, please send us a request here.

TB Determined

Good news in the fight to stop one of the world’s oldest diseases

We’ve finally moved into the next phase of the fight against tuberculosis.


When you work in global health, you see a lot of sickness and tragedy. You never get used to it, but after years of visiting hospitals and clinics, I thought I knew generally what to expect.

Nothing could prepare me, though, for the drug resistant tuberculosis ward I visited in Durban, South Africa in 2009. Every bed was filled, and the waiting list for admission was more than 80 names long. The worst part was the floor that was just for children, including several infants. One baby had XDR-TB, the deadliest and most difficult to treat form of drug-resistant TB. It was truly awful to see.

Soon, however, TB hospitals in South Africa may look very different. Recent scientific breakthroughs mean that many of the wards that used to be full of patients may one day be filled with empty beds instead. That’s a testament to the incredible efforts of TB researchers around the world. One of those amazing scientists is Dr. Andreas Diacon, who founded an organization called TASK.

Dr. Diacon started his career as a TB specialist in Switzerland, where he rarely treated more than five patients at once. TB kills more people than any other infectious disease, but few of them are in level 4 countries like Switzerland. Because he was able to spend so much time with each patient, he got to know the ins and outs of the disease better than most. He eventually ended up in Cape Town, overseeing a clinical trial for the first new TB drug in decades.

TB research stalled in the late 20th century, because existing drugs were seen as sufficient, and there was little financial incentive to create new ones. In 2005, Dr. Diacon created TASK to help accelerate the development pipeline for novel TB treatments. The organization started with a staff of five and has grown to 180 employees. They’ve overseen trials of multiple drugs that are now being used to cure patients, including some with drug-resistant TB.

Drug resistance develops when a TB patient takes an insufficient amount of drugs to cure the disease. If a patient doesn’t finish a full course of medication, the bacteria that causes TB can mutate and become resistant to the most common forms of treatment. That mutated bacteria can then spread to other people. About one out of every 20 patients that Dr. Diacon sees has some form of drug resistance.

Even XDR-TB is curable, but not everyone responds to the treatment, and it is pretty brutal. The most common method requires daily injections for up to two years. Because those injections can only be done by a professional, patients who don’t live near a clinic often have to remain hospitalized even after they’re no longer contagious. The drugs can cause a whole range of terrible side effects, including nausea, fatigue, and even hearing loss.

Luckily, there appears to be a better way to treat XDR-TB. Researchers have identified a new three-drug cocktail that requires only six months of treatment. Instead of painful injections, patients take a fixed number of pills (the exact number depends on your weight and age) once a day.

The new course has fewer negative side effects than the injectable one, and there’s no risk of causing deafness. It’s also outpatient based, so people don’t have to stay in the hospital while receiving treatment. Plus, it’s cheaper than other treatments.

Some of these new drugs are already saving lives in South Africa. The country has the highest rate of drug-resistant TB infections per capita in the world, in large part because of the ongoing HIV epidemic (three out of every five TB patients in South Africa are also HIV-positive). With the old, injectable treatment, only 60 percent of those patients were still alive after 50 weeks of treatment. Today, with the new three-drug cocktail, 87 percent survive. That’s a remarkable increase.

Tuberculosis has haunted humanity for millennia—it’s even been found in Egyptian mummies. For most of that time, we had no clue how to stop it. Scientists finally found a cure in the mid-1900s, but it was imperfect, and innovation stalled for decades. Thanks to brilliant scientists in South Africa and around the world—including the team at TASK—we’ve finally moved into the next phase of the fight against tuberculosis.

Meet more of my heroes in the field